Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple active site corrections for docking and virtual screening.

Guy P A Vigers1, James P Rizzi

  • 1Array BioPharma Inc., 3200 Walnut St, Boulder, Colorado 80301, USA. gvigers@arraybiopharma.com

Journal of Medicinal Chemistry
|December 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3-[(1<i>S</i>,2<i>S</i>,3<i>R</i>)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.

Journal of medicinal chemistry·2019
Same author

Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).

Journal of medicinal chemistry·2018
Same author

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.

Cancer research·2016
Same author

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.

Nature·2016
Same author

Targeting renal cell carcinoma with a HIF-2 antagonist.

Nature·2016
Same author

Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.

ACS medicinal chemistry letters·2014
Same journal

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same journal

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Journal of medicinal chemistry·2026
Same journal

3',4'-Isopropylidene-α-galactosylceramide Enables Multidose Th1 Adjuvanticity Despite Limited Serial Serum IFN-γ Responsiveness.

Journal of medicinal chemistry·2026
Same journal

A Bioorthogonally Cleavable <i>N</i>-Oxide Linker for Prodrug Design: Elucidating the Structure-Cyclization Kinetics Relationships for Controlled Drug Release.

Journal of medicinal chemistry·2026
Same journal

A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.

Journal of medicinal chemistry·2026
Same journal

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026
See all related articles

Docking programs struggle to rank ligands accurately. A new statistical correction, multiple active site correction (MASC), significantly improves ligand ranking for structure-based drug design.

Area of Science:

  • Computational chemistry
  • Structural biology
  • Drug discovery

Background:

  • Molecular docking programs can predict ligand binding conformations.
  • Current programs often fail to accurately rank multiple potential ligands within a single active site.
  • This limitation hinders structure-based drug design.

Purpose of the Study:

  • To evaluate the performance of FlexX and Gold docking programs in matching ligands to active sites.
  • To introduce and validate a novel statistical correction method, Multiple Active Site Correction (MASC).
  • To assess MASC's effectiveness in improving ligand ranking for drug design.

Main Methods:

  • Tested docking accuracy of FlexX and Gold against multiple experimentally determined complexes.
  • Developed and applied the Multiple Active Site Correction (MASC) statistical method.

Related Experiment Videos

  • Validated MASC using an extended dataset of 63 cocrystals and a virtual screening experiment.

    • Main Results:

    • Standard docking scores from FlexX and Gold showed inconsistent ligand-site matching.
    • MASC significantly improved the accuracy of ligand-site matching in all tested scenarios.
    • The correction method demonstrated robust performance across diverse datasets.

    Conclusions:

    • Existing docking programs require enhancement for reliable ligand ranking.
    • MASC offers a significant improvement for molecular docking accuracy.
    • This correction method has broad applicability in structure-based drug design and virtual screening.